217 related articles for article (PubMed ID: 9704831)
1. Topical calcipotriene for morphea/linear scleroderma.
Cunningham BB; Landells ID; Langman C; Sailer DE; Paller AS
J Am Acad Dermatol; 1998 Aug; 39(2 Pt 1):211-5. PubMed ID: 9704831
[TBL] [Abstract][Full Text] [Related]
2. Comparative study of calcipotriene (MC 903) ointment and fluocinonide ointment in the treatment of psoriasis.
Bruce S; Epinette WW; Funicella T; Ison A; Jones EL; Loss R; McPhee ME; Whitmore C
J Am Acad Dermatol; 1994 Nov; 31(5 Pt 1):755-9. PubMed ID: 7929921
[TBL] [Abstract][Full Text] [Related]
3. Topical calcipotriene has no short-term effect on calcium and bone metabolism of patients with psoriasis.
Guzzo C; Lazarus G; Goffe BS; Katz HI; Lowe NJ; Pincus SH
J Am Acad Dermatol; 1996 Mar; 34(3):429-33. PubMed ID: 8609254
[TBL] [Abstract][Full Text] [Related]
4. Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement.
Lebwohl M; Yoles A; Lombardi K; Lou W
J Am Acad Dermatol; 1998 Sep; 39(3):447-50. PubMed ID: 9738781
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis: results of two multicenter, randomized, double-blind, vehicle-controlled, phase III clinical trials.
Feldman SR; Matheson R; Bruce S; Grande K; Markowitz O; Kempers S; Brundage T; Wyres M;
Am J Clin Dermatol; 2012 Aug; 13(4):261-71. PubMed ID: 22587791
[TBL] [Abstract][Full Text] [Related]
6. Preliminary study of the efficacy and tolerability of combination therapy with calcipotriene ointment 0.005% and tacrolimus ointment 0.1% in the treatment of stable plaque psoriasis.
Tirado-Sánchez A; Ponce-Olivera RM
Cutis; 2012 Sep; 90(3):140-4. PubMed ID: 23094314
[TBL] [Abstract][Full Text] [Related]
7. Topical application of calcipotriene and corticosteroids: combination regimens.
Lebwohl M
J Am Acad Dermatol; 1997 Sep; 37(3 Pt 2):S55-8. PubMed ID: 9344186
[TBL] [Abstract][Full Text] [Related]
8. Combination of calcipotriene (Dovonex) ointment and tazarotene (Tazorac) gel versus clobetasol ointment in the treatment of plaque psoriasis: a pilot study.
Bowman PH; Maloney JE; Koo JY
J Am Acad Dermatol; 2002 Jun; 46(6):907-13. PubMed ID: 12063489
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D and topical therapy.
Lebwohl M
Cutis; 2002 Nov; 70(5 Suppl):5-8. PubMed ID: 12467332
[TBL] [Abstract][Full Text] [Related]
10. Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial.
Kircik LH
J Drugs Dermatol; 2011 Aug; 10(8):878-82. PubMed ID: 21818509
[TBL] [Abstract][Full Text] [Related]
11. Calcipotriene ointment 0.005% for psoriasis: a safety and efficacy study. Calcipotriene Study Group.
Highton A; Quell J
J Am Acad Dermatol; 1995 Jan; 32(1):67-72. PubMed ID: 7822519
[TBL] [Abstract][Full Text] [Related]
12. The use of topical calcipotriene/calcipotriol in conditions other than plaque-type psoriasis.
Thiers BH
J Am Acad Dermatol; 1997 Sep; 37(3 Pt 2):S69-71. PubMed ID: 9344189
[TBL] [Abstract][Full Text] [Related]
13. Double-blind, placebo-controlled study of oral calcitriol for the treatment of localized and systemic scleroderma.
Hulshof MM; Bouwes Bavinck JN; Bergman W; Masclee AA; Heickendorff L; Breedveld FC; Dijkmans BA
J Am Acad Dermatol; 2000 Dec; 43(6):1017-23. PubMed ID: 11100017
[TBL] [Abstract][Full Text] [Related]
14. Effect of calcipotriene plus betamethasone dipropionate topical suspension on the hypothalamic-pituitary-adrenal axis and calcium homeostasis in subjects with extensive psoriasis vulgaris: an open, non-controlled, 8-week trial.
Silver S; Tuppal R; Gupta AK; Clonier F; Olesen M; Leeder R; Taraska V
J Drugs Dermatol; 2013 Aug; 12(8):882-7. PubMed ID: 23986161
[TBL] [Abstract][Full Text] [Related]
15. Calcipotriene ointment applied once a day for psoriasis: a double-blind, multicenter, placebo-controlled study.
Pariser DM; Pariser RJ; Breneman D; Lebwohl M; Kalb R; Moore J; Moss H; Parker C; Fiedler V
Arch Dermatol; 1996 Dec; 132(12):1527. PubMed ID: 8961897
[No Abstract] [Full Text] [Related]
16. Topical calcipotriol ointment in the treatment of morphea.
Tay YK
J Dermatolog Treat; 2003 Dec; 14(4):219-21. PubMed ID: 14660267
[TBL] [Abstract][Full Text] [Related]
17. A multicenter, randomized, double-blind study of the efficacy and safety of calcipotriene foam, 0.005%, vs vehicle foam in the treatment of plaque-type psoriasis of the scalp.
Feldman SR; Mills M; Brundage T; Eastman WJ
J Drugs Dermatol; 2013 Mar; 12(3):300-6. PubMed ID: 23545912
[TBL] [Abstract][Full Text] [Related]
18. Spotlight on calcipotriene/betamethasone dipropionate in psoriasis vulgaris of the trunk, limbs, and scalp.
McCormack PL
Am J Clin Dermatol; 2011 Dec; 12(6):421-4. PubMed ID: 21967117
[TBL] [Abstract][Full Text] [Related]
19. Short- and long-term safety assessment of a two-compound ointment containing calcipotriene/betamethasone dipropionate (Taclonex/Daivobet/Dovobet ointment): hypothalamic-pituitary-adrenal axis function in patients with psoriasis vulgaris.
Fleming C; Ganslandt C; Leese GP
J Drugs Dermatol; 2010 Aug; 9(8):969-74. PubMed ID: 20684147
[TBL] [Abstract][Full Text] [Related]
20. Combined treatment with calcipotriol ointment and low-dose ultraviolet A1 phototherapy in childhood morphea.
Kreuter A; Gambichler T; Avermaete A; Jansen T; Hoffmann M; Hoffmann K; Altmeyer P; von Kobyletzki G; Bacharach-Buhles M
Pediatr Dermatol; 2001; 18(3):241-5. PubMed ID: 11438008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
